[go: up one dir, main page]

HUP9801396A2 - G-protein-funkció gátlására és daganatos betegségek kezelésére alkalmas 11-piperidilidén-5H-benzo[5,6]ciklohepta[1,2-b]piridin-származékok, alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények - Google Patents

G-protein-funkció gátlására és daganatos betegségek kezelésére alkalmas 11-piperidilidén-5H-benzo[5,6]ciklohepta[1,2-b]piridin-származékok, alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP9801396A2
HUP9801396A2 HU9801396A HUP9801396A HUP9801396A2 HU P9801396 A2 HUP9801396 A2 HU P9801396A2 HU 9801396 A HU9801396 A HU 9801396A HU P9801396 A HUP9801396 A HU P9801396A HU P9801396 A2 HUP9801396 A2 HU P9801396A2
Authority
HU
Hungary
Prior art keywords
pirydine
piperidylidene
cyclohepta
benzo
inhibition
Prior art date
Application number
HU9801396A
Other languages
English (en)
Inventor
Adriano Afonso
Joseph M. Kelly
Ronald L. Wolin
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of HUP9801396A2 publication Critical patent/HUP9801396A2/hu
Publication of HUP9801396A3 publication Critical patent/HUP9801396A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HU9801396A 1995-03-24 1996-03-20 11-piperidylidene-5h-benzo[5,6]cyclohepta[1,2-b]pirydine-derivatives useful for inhibition of g-protein function and for treatment of proliferative diseases, use thereof and pharmaceutical compositions containing these compounds HUP9801396A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/410,442 US5684013A (en) 1995-03-24 1995-03-24 Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases

Publications (2)

Publication Number Publication Date
HUP9801396A2 true HUP9801396A2 (hu) 1999-05-28
HUP9801396A3 HUP9801396A3 (en) 2000-03-28

Family

ID=23624752

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9801396A HUP9801396A3 (en) 1995-03-24 1996-03-20 11-piperidylidene-5h-benzo[5,6]cyclohepta[1,2-b]pirydine-derivatives useful for inhibition of g-protein function and for treatment of proliferative diseases, use thereof and pharmaceutical compositions containing these compounds

Country Status (15)

Country Link
US (3) US5684013A (hu)
EP (1) EP0814807B1 (hu)
JP (1) JP3001982B2 (hu)
KR (1) KR19980703257A (hu)
AR (1) AR003936A1 (hu)
AT (1) ATE239472T1 (hu)
AU (1) AU708244B2 (hu)
CA (1) CA2216291C (hu)
DE (1) DE69627993T2 (hu)
ES (1) ES2198481T3 (hu)
HU (1) HUP9801396A3 (hu)
IL (1) IL117603A (hu)
NZ (1) NZ305133A (hu)
TW (1) TW473477B (hu)
WO (1) WO1996030017A1 (hu)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
GB9604311D0 (en) * 1996-02-29 1996-05-01 Merck & Co Inc Inhibitors of farnesyl-protein transferase
US6001835A (en) * 1996-04-03 1999-12-14 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6117641A (en) 1996-04-11 2000-09-12 Mitotix, Inc. Assays and reagents for identifying anti-fungal agents and uses related thereto
US6727082B1 (en) 1996-04-11 2004-04-27 Gpc Biotech Inc. Assays and reagents for identifying anti-fungal agents, and uses related thereto
CA2251593A1 (en) 1996-04-11 1997-10-16 Mitotix, Inc. Assays and reagents for identifying anti-fungal agents, and uses related thereto
US5945429A (en) * 1996-09-13 1999-08-31 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5985879A (en) * 1996-09-13 1999-11-16 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US5994364A (en) 1996-09-13 1999-11-30 Schering Corporation Tricyclic antitumor farnesyl protein transferase inhibitors
US5861395A (en) * 1996-09-13 1999-01-19 Schering Corporation Compounds useful for inhibition of farnesyl proteins transferase
US6030982A (en) * 1996-09-13 2000-02-29 Schering Corporationm Compounds useful for inhibition of farnesyl protein transferase
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
US6040305A (en) * 1996-09-13 2000-03-21 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6130229A (en) * 1996-10-09 2000-10-10 Schering Corporation Tricyclic compounds having activity as RAS-FPT inhibitors
US6228865B1 (en) 1997-06-17 2001-05-08 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6426352B1 (en) 1997-06-17 2002-07-30 Schering Corporation Sulfonamide inhibitors of farnesyl-protein transferase
US6239140B1 (en) 1997-06-17 2001-05-29 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6211193B1 (en) 1997-06-17 2001-04-03 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6576639B1 (en) 1997-06-17 2003-06-10 Schering Corporation Compounds for the inhibition of farnesyl protein transferase
US5877177A (en) * 1997-06-17 1999-03-02 Schering Corporation Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5925639A (en) * 1997-06-17 1999-07-20 Schering Corporation Keto amide derivatives useful as farnesyl protein transferase inhibitors
US6689789B2 (en) * 1997-06-17 2004-02-10 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6218401B1 (en) 1997-06-17 2001-04-17 Schering Corporation Phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase
US6051582A (en) * 1997-06-17 2000-04-18 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6159984A (en) 1997-06-17 2000-12-12 Schering Corporation Farnesyl protein transferase inhibitors
US5958940A (en) * 1997-09-11 1999-09-28 Schering Corporation Tricyclic compounds useful as inhibitors of farnesyl-protein transferase
US6632455B2 (en) 1997-12-22 2003-10-14 Schering Corporation Molecular dispersion composition with enhanced bioavailability
US6372747B1 (en) 1998-12-18 2002-04-16 Schering Corporation Farnesyl protein transferase inhibitors
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
EP1088821A1 (en) * 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
PE20020635A1 (es) 2000-11-29 2002-07-11 Schering Corp Compuestos triciclicos como inhibidores de la farnesil transferasa
EP1656156A2 (en) 2003-08-13 2006-05-17 Children's Hospital Medical Center Mobilization of hematopoietic cells
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EA018917B1 (ru) 2006-04-19 2013-11-29 Новартис Аг 6-о-замещенные бензоксазолы и бензотиазолы и способы подавления передачи сигналов от csf-1r
CA2770486C (en) 2006-09-22 2014-07-15 Merck Sharp & Dohme Corp. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
JP5330274B2 (ja) 2007-03-01 2013-10-30 ノバルティス アーゲー Ｐｉｍキナーゼ阻害剤およびその使用方法
ES2452349T3 (es) 2007-05-21 2014-04-01 Novartis Ag Inhibidores de CSF-1R, composiciones, y métodos de uso
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
CN102480966B (zh) 2009-06-12 2015-09-16 达娜-法勃肿瘤研究所公司 融合的杂环化合物及其用途
CN104945382B (zh) 2009-10-14 2020-02-07 默沙东公司 提高p53活性的取代的哌啶和其用途
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
EA201290919A1 (ru) 2010-03-16 2013-03-29 Дана-Фарбер Кэнсер Инститьют, Инк. Индазольные соединения и их применение
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN103328971B (zh) 2010-07-28 2016-09-28 维里德克斯有限责任公司 急性髓细胞性白血病应答法尼基转移酶抑制剂治疗的测定方法
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
EP3587574B1 (en) 2010-08-17 2022-03-16 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
EP3327125B1 (en) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
CA2831730A1 (en) 2011-04-21 2012-10-26 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
EP3453762B1 (en) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
KR20150060724A (ko) 2012-09-28 2015-06-03 머크 샤프 앤드 돔 코포레이션 Erk 억제제인 신규 화합물
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
DK2925888T3 (en) 2012-11-28 2017-12-18 Merck Sharp & Dohme COMPOSITIONS AND METHODS OF CANCER TREATMENT
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015058140A1 (en) 2013-10-18 2015-04-23 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
US20160264551A1 (en) 2013-10-18 2016-09-15 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
CA2972239A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3273966B1 (en) 2015-03-27 2023-05-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
EP3307728A4 (en) 2015-06-12 2019-07-17 Dana Farber Cancer Institute, Inc. COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND CHINESE INHIBITORS
PT3640345T (pt) 2015-08-17 2021-12-29 Kura Oncology Inc Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase
AU2016319125B2 (en) 2015-09-09 2021-04-08 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
KR20190082247A (ko) 2016-11-03 2019-07-09 쿠라 온콜로지, 인크. 파르네실전달효소 억제제를 이용하여 암 환자를 치료하는 방법
KR102702926B1 (ko) 2017-04-13 2024-09-06 사이로파 비.브이. 항-sirp 알파 항체
EP3706747B1 (en) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
AU2019295632B2 (en) 2018-06-25 2025-03-06 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833355A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
WO2020140098A1 (en) 2018-12-28 2020-07-02 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP4076460A4 (en) 2019-12-17 2023-11-15 Merck Sharp & Dohme LLC PRMT5 INHIBITORS
IL322769A (en) 2023-03-02 2025-10-01 Carcimun Biotech Gmbh Means and methods for diagnosing cancer and/or acute inflammatory disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4355036A (en) * 1980-06-19 1982-10-19 Schering Corporation Tricyclic-substituted piperidine antihistamines
US4282233B1 (en) * 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US4826853A (en) * 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
EP0339978B1 (en) * 1988-04-28 1996-08-21 Schering Corporation Fused polycyclic compounds, compositions, methods of manufacture, and their use as PAF antagonists, antihistamines and/or antiinflammatory agents
US5104876A (en) * 1988-04-28 1992-04-14 Schering Corporation Benzopyrido piperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and methods of use
US5393890A (en) * 1988-06-02 1995-02-28 Ajinomoto Co., Inc. Piperidine derivatives and hypotensives containing the same
US4863931A (en) * 1988-09-15 1989-09-05 Schering Corporation Antihistaminic fluoro substituted benzocycloheptapyridines
US5141851A (en) * 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
US6083917A (en) * 1990-04-18 2000-07-04 Board Of Regents, The University Of Texas System Methods and compositions for the identification, characterization and inhibition of farnesyltransferase
ZA914764B (en) * 1990-06-22 1992-03-25 Schering Corp Bis-benzo or benzopyrido cyclohepta piperidene,piperidylidene and piperazine compounds,compositions and methods of use
US5416091A (en) * 1990-12-18 1995-05-16 Burroughs Wellcome Co. Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
KR920014799A (ko) * 1991-01-18 1992-08-25 나오가따 다이도 신규벤조[5,6]시클로헵타[1,2-b]피리딘 유도체 및 이를 함유하는 항알레르기제
US5340828A (en) * 1991-09-30 1994-08-23 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
WO1993023400A1 (en) * 1992-05-19 1993-11-25 Schering Corporation Pentacyclic antihistamines
US5643909A (en) * 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives

Also Published As

Publication number Publication date
JP3001982B2 (ja) 2000-01-24
ES2198481T3 (es) 2004-02-01
AR003936A1 (es) 1998-09-30
AU708244B2 (en) 1999-07-29
ATE239472T1 (de) 2003-05-15
JPH10505102A (ja) 1998-05-19
IL117603A (en) 2001-01-28
AU5307296A (en) 1996-10-16
EP0814807A1 (en) 1998-01-07
IL117603A0 (en) 1996-07-23
EP0814807B1 (en) 2003-05-07
DE69627993D1 (de) 2003-06-12
US5684013A (en) 1997-11-04
CA2216291C (en) 2001-06-05
DE69627993T2 (de) 2004-02-26
MX9707191A (es) 1997-11-29
WO1996030017A1 (en) 1996-10-03
TW473477B (en) 2002-01-21
HUP9801396A3 (en) 2000-03-28
NZ305133A (en) 1999-11-29
US5703090A (en) 1997-12-30
CA2216291A1 (en) 1996-10-03
KR19980703257A (ko) 1998-10-15
US5958939A (en) 1999-09-28

Similar Documents

Publication Publication Date Title
HUP9801396A3 (en) 11-piperidylidene-5h-benzo[5,6]cyclohepta[1,2-b]pirydine-derivatives useful for inhibition of g-protein function and for treatment of proliferative diseases, use thereof and pharmaceutical compositions containing these compounds
HUP9800456A3 (en) 11-(4-piperidylidene)-5h-benzo[5,6]cyclohepta[1,2-b]-pyridine derivatives useful for inhibition of g-protein function and for treatment of proliferative diseases, pharmaceutical compositions containing these compounds and use thereof
IL125062A (en) Tricyclic amides and pharmaceutical compositions containing them for inhibition of g-protein function and for treatment of proliferative diseases
HUP9801331A3 (en) Tricyclic amide and urea derivatives useful for inhibition of g-protein function and for treatment of proliferative diseases, novel tricyclic amide and urea derivatives, use thereof, pharmaceutical compositions containing these compounds as active ...
AU5189196A (en) Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
AU5307796A (en) Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
HUP0001607A3 (en) Thienopyrimidine derivatives, pharmaceutical compositions containing them, process for their preparation and use of the compounds
EP0707446A4 (en) PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATING NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOM COMPLEXES
HUP9801883A3 (en) Piperazine-derivatives for inhibiting of farnesyl-protein transferase, preparation and use thereof, pharmaceutical compositions containing these compounds
HUP0001267A3 (en) Use of rapamycin derivatives for the preparation of pharmaceutical compositions treating vasculopathies
IL117957A0 (en) Pharmaceutical compositions for the treatment of impotence
HUP9901159A3 (en) Substituted benzylaminopiperidine derivatives and use thereof, pharmaceutical compositions containing these compounds
SI1156049T1 (en) Substituted heterocyclic compounds, their process of preparation and pharmaceutical compositions containing them
HUP9900901A3 (en) A pharmaceutical composition containing n-chlorophenylcarbamates and n-chlorophenylthiocarbamates for inhibiting the growth of viruses and cancers
HUP9800466A3 (en) N-acyl-thieno[3,2-b]azepine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP9801993A3 (en) Ascomycin derivatives and their use for preparation of pharmaceutical compositions, process for their preparation and pharmaceutical compositions containing them
IL117620A0 (en) Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same
IL117797A0 (en) Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
HUP9903684A3 (en) Use of olanzapine for the preparation of pharmaceutical compositions treating depression
IL116539A0 (en) Compositions for transdermal delivery of acid-labile drugs
EG23781A (en) Pharmaceutical composition containing tiagabine hydrochloride and the process for its preparation
HUP9601680A3 (en) Benzisothiazolyl-substituted aminomethyl-chromanes, pharmaceutical compositions containing the same, process for their preparation and use of the compounds
IL117970A (en) Pharmaceutical compositions containing olanzapine for treating nicotine withdrawal
AP9801275A0 (en) Use of tricyclic 1,4-dihydro-1,4-dioxo-1H-naphthalene derivatives resulting novel compounds and therapeutical use thereof
HUP9602324A3 (en) Piperidinyl-methyl-oxazolidinon derivatives, pharmaceutical compositions containing the same, process for the preparation of the compounds and use of them